Renalytix AI Plc (GB:RENX) has released an update.
Renalytix PLC has announced a significant management change, promoting Howard Doran from Chief Business Officer to President, effective April 30, 2024, as the current President, Thomas McLain, steps down. CEO James McCullough expressed gratitude to McLain for his role in achieving key milestones for the company’s flagship product, KidneyIntelX, and anticipates Doran to spearhead the global sales efforts with his proven track record. Renalytix is a leading in-vitro diagnostics company focused on kidney health and has developed the KidneyIntelX test to assess the risk of rapid kidney function decline.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
